Date:2/20/2011

. However, while NxStage may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, whether as a result of new information, future events, or otherwise. These forward-looking statements should not be relied upon as representing NxStage's expectations or beliefs as of any date subsequent to the date of this press release.Contact:Kristen K. Sheppard, Esq.Investor Relationsksheppard@nxstage.com
'/>"/>

SOURCE NxStage Medical, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. In Celebration of the 31st Annual Dialysis Conference, NxStage® Announces Over 5,000 Patients Using the System One™ for Home Hemodialysis
2. NxStage® Reports Fourth Quarter and Full-Year 2010 Financial Results; Revenue Growth Exceeds Company Guidance
3. NxStage® to Report Fourth Quarter and Full Year 2010 Financial Results
4. NxStage® Appoints Nancy J. Ham to Its Board of Directors and Announces Resignation of Board Member Jonathan T. Silverstein
5. First NxStage® Home Hemodialysis Patients Celebrate Seven-Year Anniversary
6. NxStage® Expands Product Portfolio With Innovative Patient Access Surveillance Solution From Vasc-Alert™
7. CHPA Applauds Introduction of The Patients Freedom to Choose Act
8. MAP Pharmaceuticals to Present Data Showing Low Migraine Recurrence Rates With LEVADEX™ in FREEDOM-301 Trial
9. MAP Pharmaceuticals to Present Additional Data Analyses From LEVADEX™ FREEDOM-301 Trial at 2010 European Headache and Migraine Trust International Congress
10. NxStage(R) Reports Significant Interim FREEDOM Study Results
11. New Clinical Study Shows RyMed InVision-Plus® IV Connector Dramatically Reduced Catheter-Related Bloodstream Infections by Over 92%